Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ertugliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 VERTIS CV cardiovascular outcomes trial evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, vs placebo, added to background standard of care treatment, in patients with type 2 diabetes and atheroscleroti...
Brand Name : Steglatro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 16, 2020
Lead Product(s) : Ertugliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?